251 related articles for article (PubMed ID: 32811475)
1. Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies.
Ma L; Luo D; Yang T; Wu S; Li M; Chen C; Zhou S; Ma L; Wu Y; Zhou Y; Cui Y
BMC Endocr Disord; 2020 Aug; 20(1):126. PubMed ID: 32811475
[TBL] [Abstract][Full Text] [Related]
2. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients.
Neggers SJ; de Herder WW; Feelders RA; van der Lely AJ
Pituitary; 2011 Sep; 14(3):253-8. PubMed ID: 21221818
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).
Muhammad A; van der Lely AJ; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; Neggers SJCMM
J Clin Endocrinol Metab; 2018 Feb; 103(2):586-595. PubMed ID: 29155991
[TBL] [Abstract][Full Text] [Related]
4. Pegvisomant Improves Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies.
Feola T; Cozzolino A; Simonelli I; Sbardella E; Pozza C; Giannetta E; Gianfrilli D; Pasqualetti P; Lenzi A; Isidori AM
J Clin Endocrinol Metab; 2019 Jul; 104(7):2892-2902. PubMed ID: 30869797
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly.
Neggers SJ; van Aken MO; Janssen JA; Feelders RA; de Herder WW; van der Lely AJ
J Clin Endocrinol Metab; 2007 Dec; 92(12):4598-601. PubMed ID: 17895318
[TBL] [Abstract][Full Text] [Related]
6. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients.
Madsen M; Poulsen PL; Orskov H; Møller N; Jørgensen JO
J Clin Endocrinol Metab; 2011 Aug; 96(8):2405-13. PubMed ID: 21632808
[TBL] [Abstract][Full Text] [Related]
7. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
[TBL] [Abstract][Full Text] [Related]
8. Effects of medical therapies for acromegaly on glucose metabolism.
Urbani C; Sardella C; Calevro A; Rossi G; Scattina I; Lombardi M; Lupi I; Manetti L; Martino E; Bogazzi F
Eur J Endocrinol; 2013 Jul; 169(1):99-108. PubMed ID: 23660641
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ
Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
11. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial.
Bonert V; Mirocha J; Carmichael J; Yuen KCJ; Araki T; Melmed S
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32754748
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant.
Neggers SJ; van Aken MO; de Herder WW; Feelders RA; Janssen JA; Badia X; Webb SM; van der Lely AJ
J Clin Endocrinol Metab; 2008 Oct; 93(10):3853-9. PubMed ID: 18647806
[TBL] [Abstract][Full Text] [Related]
14. A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues.
Franck SE; Korevaar TIM; Petrossians P; Daly AF; Chanson P; Jaffrain-Réa ML; Brue T; Stalla GK; Carvalho D; Colao A; Hána V; Delemer B; Fajardo C; van der Lely AJ; Beckers A; Neggers SJCMM
Eur J Endocrinol; 2017 Apr; 176(4):421-431. PubMed ID: 28100630
[TBL] [Abstract][Full Text] [Related]
15. Pegvisomant in acromegaly: a multicenter real-life study in Argentina.
Basavilbaso NXG; Ballarino MC; Bruera D; Bruno OD; Chervin AB; Danilowicz K; Fainstein-Day P; Fidalgo SG; Frigeri A; Glerean M; Guelman R; Isaac G; Katz DA; Knoblovits P; Librandi F; Montes ML; Mallea-Gil MS; Manavela M; Mereshian P; Moncet D; Pignatta A; Rogozinsky A; Sago LR; Servidio M; Spezzi M; Stalldecker G; Tkatch J; Vitale NM; Guitelman M
Arch Endocrinol Metab; 2019 Aug; 63(4):320-327. PubMed ID: 31460622
[TBL] [Abstract][Full Text] [Related]
16. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
17. Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant.
Strasburger CJ; Mattsson A; Wilton P; Aydin F; Hey-Hadavi J; Biller BMK
Eur J Endocrinol; 2018 Apr; 178(4):321-329. PubMed ID: 29371335
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.
De Marinis L; Bianchi A; Fusco A; Cimino V; Mormando M; Tilaro L; Mazziotti G; Pontecorvi A; Giustina A
Pituitary; 2007; 10(3):227-32. PubMed ID: 17484056
[TBL] [Abstract][Full Text] [Related]
19. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.
Trainer PJ; Ezzat S; D'Souza GA; Layton G; Strasburger CJ
Clin Endocrinol (Oxf); 2009 Oct; 71(4):549-57. PubMed ID: 19438906
[TBL] [Abstract][Full Text] [Related]
20. The German ACROSTUDY: past and present.
Buchfelder M; Schlaffer S; Droste M; Mann K; Saller B; Brübach K; Stalla GK; Strasburger CJ;
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S3-S10. PubMed ID: 19684061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
